Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog(®)) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study

BACKGROUND: MYL-1601D is a proposed biosimilar of originator insulin aspart, Novolog(®)/NovoRapid(®) (Ref-InsAsp-US/Ref-InsAsp-EU). OBJECTIVE: This study assessed the immunogenicity, efficacy, and safety of MYL-1601D with Ref-InsAsp-US in patients with type 1 diabetes mellitus (T1D). METHODS: This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Blevins, Thomas C., Raiter, Yaron, Sun, Bin, Donnelly, Charles, Shapiro, Roxann, Chullikana, Anoop, Rao, Anita, Vashishta, Laxmikant, Ranganna, Gopinath, Barve, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649481/
https://www.ncbi.nlm.nih.gov/pubmed/36114990
http://dx.doi.org/10.1007/s40259-022-00554-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649481/
https://www.ncbi.nlm.nih.gov/pubmed/36114990
http://dx.doi.org/10.1007/s40259-022-00554-6

Ejemplares similares